Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JS005 in adults with moderate-to-severe chronic plaque psoriasis
CTR20232116Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of roconkibart in psoriasis, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jul 2023; status: completed.
02
Drugs
roconkibart
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20232116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232116.